Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Theriva Biologics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −4 vs. Q3 2022
- Shares held
- 1.05M
- −110.7K (−9.5%) vs. Q3 2022
- Total value
- $477.1K
- −$673.9K (−58.6%) vs. Q3 2022
- New holders
- 1
- 6 more added
- Sold out
- 5
- 6 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 525,367 | $238.9K | 0.00% | +282+0.1% | Added |
| BlackRock Inc. | 190,169 | $86.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 116,301 | $52.0K | 0.00% | −280−0.2% | Reduced |
| State Street Corp | 48,691 | $22.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 35,699 | $16.2K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 32,510 | $15.0K | 0.00% | +800+2.5% | Added |
| Virtu Financial LLC | 28,972 | $13.0K | 0.00% | +16,525+132.8% | Added |
| Bridgeway Capital Management, LLC | 28,528 | $13.0K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 13,566 | $6.17K | 0.00% | −10.0% | Reduced |
| Fisher Asset Management, LLC | 12,569 | $6.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 11,990 | $5.45K | 0.00% | −400−3.2% | Reduced |
| UBS Group AG | 5,015 | $2.31K | 0.00% | −1,751−25.9% | Reduced |
| Morgan Stanley | 671 | $305 | 0.00% | +373+125.2% | Added |
| Wells Fargo & Company | 108 | $49 | 0.00% | +3+2.9% | Added |
| Bank of America Corp | 24 | $11 | 0.00% | +18+300.0% | Added |
| Steward Partners Investment Advisory, LLC | 14 | $6 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 9 | $4 | 0.00% | +9 | New |
| Royal Bank of Canada | 7 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 145 | $0 | 0.00% | −221−60.4% | Reduced |
| Advisor Group Holdings, Inc. | 47 | $0 | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 26 | $0 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 382 | – | – | −3,443−90.0% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −56,077−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −31,704−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −18,352−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −16,408−100.0% | Sold out |
| Focused Wealth Management, Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |